Summary of patient characteristics
| . | All patients . | Reduced treatment* . | Standard treatment* . | |||
|---|---|---|---|---|---|---|
| Frequency . | Percent . | Frequency . | Percent . | Frequency . | Percent . | |
| National group | ||||||
| Children's Oncology Group | 101 | 43 | 40 | 43 | 44 | 46 |
| Société Française d'Oncologie Pédiatrique | 98 | 42 | 39 | 41 | 39 | 41 |
| United Kingdom Children's Cancer Study Group | 36 | 15 | 15 | 16 | 13 | 14 |
| Sex | ||||||
| Male | 185 | 79 | 75 | 80 | 77 | 80 |
| Female | 50 | 21 | 19 | 20 | 19 | 20 |
| Age, y | ||||||
| 0-4 | 47 | 20 | 15 | 16 | 22 | 23 |
| 5-9 | 97 | 42 | 39 | 41 | 44 | 46 |
| 10-14 | 64 | 27 | 31 | 33 | 20 | 21 |
| 15-19 | 27 | 12 | 9 | 10 | 10 | 10 |
| Histology | ||||||
| BL/BLL/B-ALL | 204 | 87 | 84 | 90 | 84 | 88 |
| Diffuse B-LC/TCRLCL | 21 | 9 | 6 | 6 | 7 | 7 |
| Other/NOS/pending | 10 | 4 | 4 | 3 | 5 | 5 |
| BM/CNS involvement | ||||||
| BM+/CNS− | 121 | 51 | 51 | 54 | 52 | 54 |
| BM−/CNS+ | 46 | 20 | 14 | 15 | 21 | 22 |
| BM+/CNS+ | 68 | 29 | 29 | 31 | 23 | 24 |
| LDH level | ||||||
| Unknown | 16 | — | 6 | — | 7 | — |
| Less than or equal to 2 times normal | 41 | 19 | 16 | 18 | 15 | 17 |
| More than 2 times normal | 178 | 81 | 72 | 82 | 74 | 83 |
| . | All patients . | Reduced treatment* . | Standard treatment* . | |||
|---|---|---|---|---|---|---|
| Frequency . | Percent . | Frequency . | Percent . | Frequency . | Percent . | |
| National group | ||||||
| Children's Oncology Group | 101 | 43 | 40 | 43 | 44 | 46 |
| Société Française d'Oncologie Pédiatrique | 98 | 42 | 39 | 41 | 39 | 41 |
| United Kingdom Children's Cancer Study Group | 36 | 15 | 15 | 16 | 13 | 14 |
| Sex | ||||||
| Male | 185 | 79 | 75 | 80 | 77 | 80 |
| Female | 50 | 21 | 19 | 20 | 19 | 20 |
| Age, y | ||||||
| 0-4 | 47 | 20 | 15 | 16 | 22 | 23 |
| 5-9 | 97 | 42 | 39 | 41 | 44 | 46 |
| 10-14 | 64 | 27 | 31 | 33 | 20 | 21 |
| 15-19 | 27 | 12 | 9 | 10 | 10 | 10 |
| Histology | ||||||
| BL/BLL/B-ALL | 204 | 87 | 84 | 90 | 84 | 88 |
| Diffuse B-LC/TCRLCL | 21 | 9 | 6 | 6 | 7 | 7 |
| Other/NOS/pending | 10 | 4 | 4 | 3 | 5 | 5 |
| BM/CNS involvement | ||||||
| BM+/CNS− | 121 | 51 | 51 | 54 | 52 | 54 |
| BM−/CNS+ | 46 | 20 | 14 | 15 | 21 | 22 |
| BM+/CNS+ | 68 | 29 | 29 | 31 | 23 | 24 |
| LDH level | ||||||
| Unknown | 16 | — | 6 | — | 7 | — |
| Less than or equal to 2 times normal | 41 | 19 | 16 | 18 | 15 | 17 |
| More than 2 times normal | 178 | 81 | 72 | 82 | 74 | 83 |
For all patients, N = 235; for reduced treatment, N = 94; and for standard treatment, N = 96.
BL indicates Burkitt lymphoma; BLL, Burkitt-like lymphoma; B-LC, B large cell; TCRLCL, T-cell–rich large-cell lymphoma; NOS, not otherwise specified; and –, not determined.
Forty-five patients were not randomized: nonresponse to COP (n = 9), progressive/persistent disease (n = 4), early death (n = 4), physician/parent refusal (n = 13), protocol violation (n = 5), and halted randomization (n = 10).